




(12) PATENT ABRIDGMENT (11) AU-B 1-37 471/78
(19) AU

- (54) SUBSTITUTED-1-THIENYL AND FURYL -2,3,4,5-TETRAHYDRO-14-3
BENZAZEPINE DERIVATIVES
- (71) SMITHKLINE CORPORATION.
- (21) 37 471/78 515 236 (22) 26.6.78
- (23) 26.6.78 (24) 26.6.78
- (43) 3.1.80 (44) 26.3.81
- (51)² CO7D 491/04 CO7D 45/04 CO7D 49/04 CO7D 223/16
CO7D 333/32 A61K 31/55 CO7C 93/14
- (72) Holden, K.G., and Yim, N C.F.
- (74) DM
- (57) Compounds have dopaminergic or anti-hypertensive activity
Claim 1. A compound of the formula:



in which:

R is hydrogen, benzyl, phenethyl, lower alkanoyl of 1-5 carbons, trifluoroacetyl, lower alkyl of 1-5 carbons, hydroxyethyl or lower alkenyl of 3-5 carbons;

R₁ is hydrogen, halo, trifluoromethyl, methylthio, trifluoromethylthio, methyl or methoxy;

R₂ and R₃ are each hydrogen, lower alkyl of 1-5 carbons, lower alkanoyl of 2-5 carbons or, when taken together, methylene or ethylene;

R₄ is hydrogen, halo, cyanomethyl, methyl or carbomethoxy; and

X is -O- or -S- ;
or the pharmaceutically acceptable nontoxic salts thereof.

APPLICATION FOR A PATENT (C)

515236

by

We

SMITHKLINE CORPORATION, of
 1500 Spring Garden Street,
 Philadelphia, Pennsylvania, 19101
 United States of America



hereby apply for the grant of a Patent for an invention entitled

"SUBSTITUTED 1-THIENYL AND FURYL-2,3,4,5-TETRAHYDRO-1H-3-BENZAZEPINE COMPOUNDS"

which is described in the accompanying ~~XXXXXXXXXX~~ complete specification.

The application is a Convention application and is based on the application(s) for patent or similar protection made in

on

APPLICATION ACCEPTED AND AMENDED
 13/2/81
 ALLOWED

Our address for service is care of DAVIES & COLLISON, Patent Attorneys, of
 1 Little Collins Street, Melbourne, in the State of Victoria, Commonwealth of Australia.

Dated this 22nd day of June, 1978

(a) *H. O. Rimington*

(a member of the firm of DAVIES & COLLISON)
 for and on behalf of the applicant

(b)

20 JUN 1978

To: THE COMMISSIONER OF PATENTS
 Davies & Collison, Melbourne and Canberra.

DECLARATION IN SUPPORT OF AN APPLICATION
FOR A PATENT OR PATENT OF ADDITION

(The declaration shall be made by the applicant, or, if the applicant is a body corporate, by a person authorized by the body corporate to make the declaration on its behalf.)

Insert full name(s) of
applicant(s).

In support of the Application made by
SMITHKLIN CORPORATION

374717A

for a ~~patent~~
~~patent of addition~~ for an invention entitled

"SUBSTITUTED 1-THIENYL AND FURYL-2,3,4,5-
TETRAHYDRO-1H-3-BENZAZEPINE COMPOUNDS"

Insert full name(s)
and address(es) of
declarant(s).

I
We
William Howard Edgerton
457 Maynard Drive
Strafford-Wayne, Pennsylvania 15087
United States of America

Delete the words which
are not applicable.

do solemnly and sincerely declare as follows:—

1. (a) ~~I am~~ the applicant ~~for the~~ patent
~~We are~~ ~~patent of addition~~

Insert full name of
applicant Company.

or (b) I am authorized by SMITHKLIN CORPORATION

Delete the words which
are not applicable.

the applicant for the ~~patent~~
~~patent of addition~~ to make this declaration on its behalf.

Delete the words which
are not applicable.

2. (a) ~~I am~~ the actual inventor ~~of the~~ invention.
~~We are~~

Insert full name(s) and
address(es) of
actual inventor(s).

or (b) KENNETH GEORGE HOLDEN of 425 Beechwood Avenue,
Haddonfield, New Jersey and NELSON CHI-FAI YIM
of 922 Cathedral Road, Philadelphia, Pennsylvania,
both in the United States of America,

are

~~is~~ the actual inventor ~~s~~ of the invention and the facts upon which the applicant

~~is~~ entitled to make the application are as follows:—

State in which
applicant(s) derive title
from actual inventor(s).

The said SMITHKLIN CORPORATION is the assignee
of the said Kenneth George Holden and
Nelson Chi-Fai Yim

Declared at Philadelphia, Pennsylvania, this 9th day of June --, 1978.

Signature(s) of
declarant(s).

SMITHKLIN CORPORATION

Attestation or other
signature is required.)

BY:

William Howard Edgerton
Director, Patent Solicitation

Initial all Alterations.

PATENTS ACT 1952

COMPLETE SPECIFICATION

(Original)

FOR OFFICE USE

Class

Int. Class

Application Number:
Lodged:

Complete Specification Lodged:
Accepted:
Published:

Priority:

Related Art:

Transmitted under
Section 49.
4 FEB 1981
is return for printing

Name of Applicant: SMITHKLINE CORPORATION

Address of Applicant: 1500 Spring Garden Street,
Philadelphia, Pennsylvania 19101,
United States of America

Actual Inventor(s): KENNETH GEORGE HOLDEN and NELSON CHI-FAI YIM

Address for Service: DAVIES & COLLISON, Patent Attorneys,
1 Little Collins Street, Melbourne, 3000.


Complete specification for the invention entitled:

"SUBSTITUTED 1-THIENYL AND FURYL-2,3,4,5-TETRAHYDRO-1H-3-
BENZAZEPINE COMPOUNDS"

The following statement is a full description of this invention,
including the best method of performing it known to us :-

This invention comprises a new group of compounds which have structures characterized by being 1-thienyl and 1-furyl-2,3,4,5-tetrahydro-1H-3-benzazepines having two hydroxy, C₁₋₅ alkoxy or C₂₋₅ alkanoyloxy substituents in the benz-ring of the benzazepine nucleus. These new compounds have utility as medicinally active compounds especially as cardiovascular agents due to their peripheral dopaminergic activity. They also demonstrate activity in animal tests which are known to predict anti-Parkinsonism activity by means of activity at the central dopamine receptors. Generally speaking therefore they may have both peripheral or central dopaminergic activity.

The structures of the compounds of this invention are specifically identified by having a thienyl or furyl hetero ring at the 1-position of the 2,3,4,5-tetrahydro-1H-3-benzazepine system. Exemplary of this new group of compounds are those represented by the following structural formulas:



in which:

R is hydrogen, phenethyl, benzyl, lower alkanoyl of from 1-5 carbon such as formyl or acetyl, trifluoroacetyl, lower alkyl of 1-5 carbon atoms, hydroxyethyl or lower alkenyl of 3-5 carbon atoms;

R¹ is hydrogen, halo, trifluoromethyl, trifluoromethylthio, methyl, ^{or methoxy} or methoxy;

1 R₂ and R₃ are each hydrogen, lower alkyl of 1-5 carbon
atoms, lower alkanoyl of 2-5 carbon atoms or, when taken
together, methylene or ethylene;

5 R₄ is hydrogen, halo such as F, Cl or Br, cyanomethyl,
carbomethoxy or methyl and

X is -O- or -S- .

10 In the above structural formulas those skilled in the art
will recognize that the hetero ring is attached at its 2' (α) or
3' (β) position. The substituents on the two hetero rings are merely
limited by the constraints of furan or thiophene chemistry but are of
course C-attached.

 The thienyl containing congeners are preferred. The furyl
congeners may be less active and more toxic than their thienyl counter-
parts.

15 A subgeneric group of compounds within the above illustrative
generic group are those of Formula I in which:

R is hydrogen or methyl;

R₁ is hydrogen or chloro;

20 R₂ and R₃ are the same and are hydrogen, methyl
or acetyl;

R₄ is hydrogen or methyl; and

X is -S- .

25 The compounds in which R₂ and R₃ are higher alkyl or alkanoyl
groups or form an alkylene chain such as the methylenedioxy-containing
compounds at the 7,8-positions as well as the N-benzyl, phenethyl or
alkanoyl containing congeners are of primary interest as intermediates.
Methylenedioxy-3-benzazepines in another series are reported in U.S.
Patent 3,795,683.


the utility of the free bases of formula I, prepared by methods well known to the art, are formed with both inorganic or organic acids, for example: maleic, fumaric, benzoic, ascorbic, pantoic, succinic, bismethylene-salicylic, methanesulfonic, ethanedisulfonic, acetic, oxalic, propionic, tartaric, salicylic, citric, gluconic, aspartic, stearic, palmitic, itaconic, glycolic, p-aminobenzoic, glutamic, benzenesulfonic, hydrochloric, hydrobromic, sulfuric, cyclohexyl-sulfamic, phosphoric and nitric acids. Similarly the quarternary salts include those prepared from organic halides such as methyl iodide, ethyl iodide or benzyl chloride, methyl tosylate or mesylate which react at the basic 3-center or at a reactive thio center. While the 1-furylbenzazepines form salts readily with strong mineral acids such as sulfuric or hydrochloric acid, such salts are less stable and hard to purify. Therefore the furyl containing compounds are best used either as the base or as a salt with an organic or weak inorganic acid.

Certain 1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines have been described in U.S. Patent 3,393,192; British Patent Specification 1,118,688; and Swiss Patent 555,831, including general methods of preparation. However these references disclose no 1-heterosubstituted compounds.

It will be obvious to one skilled in the art that the compounds of Formula I may be present as diastereoisomers which may be resolved into d or l optical isomers. Resolution of the optical isomers may be conveniently accomplished by fractional crystallization of the salts of the base form or of solid derivatives thereof with optically active acids from appropriate solvents. Unless otherwise specified herein or in the claims, it is intended to include all isomers, whether separated or mixtures thereof. Where isomers are separated, the desired pharmacological activity will usually predominate in one of the isomers,

most often in the d-isomer.

The compounds of Formula I in which R is hydrogen are generally prepared from intermediates of the following formula:



in which R is hydrogen; ~~lower alkyl, benzyl or lower alkenyl~~; R_1 and X are as defined above; R_2 and R_3 are lower alkyl or together are lower alkylene; and R_4 is hydrogen or a chemically inert substituent of the group described above, by means of an intramolecular cyclization effected by reaction with a reagent such as sulfuric acid alone or mixed with suitable solvents such as trifluoroacetic acid, polyphosphoric acid or a similar dehydrating agent.

Mixed alkoxy substituted compounds are prepared by selecting the proper heteroarylethylamine starting material.

The cyclization is best run to form the methylenedioxy or dimethoxy ethers, then these ether groups are optionally taken off using a mild splitting agent such as boron trichloride for the methylenedioxy or tribromide for the dimethoxy ether.

The heteroarylethylamines ^(III)~~(IV)~~ which are used as starting materials for this method are either known or are prepared by methods similar to those disclosed in the illustrative examples.

1

The 6-substituted compounds are alternatively prepared by oxidizing a 7,8-dihydroxy-1-(furyl or thienyl)-2,3,4,5-tetrahydro-1H-3-benzazepine with 2,3-dichloro-5,6-dicyano-1,4-benzoquinone or similar hydroquinone-oxidizing agent to form the 7,8-dione. This is then reacted with a quinone additive agent, a nucleophilic reagent, such as methyl mercaptan, trifluoromethyl mercaptan, hydrogen chloride or hydrogen bromide (in the case where no acid sensitive centers are present) in methanol at about room temperature to give the desired 6-substituted compound.

)

The 6-bromo containing compound may optionally serve as an intermediate in a number of ways such as for preparing the 6-chloro or 6-iodo congeners or the 6-lithium intermediates. The latter lithium compounds can be reacted with a number of other conventional reactants to introduce 6-substituents such as with iodine or hexachloroethane to introduce iodo or chloro.

To prepare the compounds of Formula I where R is hydroxyethyl, lower alkyl or lower alkenyl, the corresponding benzazepines wherein R is hydrogen are alkylated by standard methods with ethylene oxide, a reactive lower alkyl halide such as the bromide or chloride or a reactive alkenyl halide such as an allyl bromide or chloride. Advantageously, to obtain the products where R₂ and/or R₃ are hydrogen the reaction with the alkylating agent is carried out on the corresponding methoxy substituted benzazepines in an inert solvent such as methanol or acetone, preferably at reflux temperature and in the presence of a basic condensing agent such as potassium hydroxide or carbonate. Treatment of the resulting product with, for example boron tribromide or other ether splitting agents gives the active hydroxy substituted benzazepines. If a reactive center such as a methylthio group is present the sulfonium quaternary salt is prepared. This may be optionally converted back to the methylthio

by heating in brine, 1N hydrobromic acid or another source of halide ions. The 3-methyl congeners are an important part of this invention.

The compounds of Formula I where R is methyl are conveniently prepared from 7,8-dimethoxy substituted benzazepines wherein R is hydrogen by reaction with formic acid/formaldehyde. Treatment of the resulting product with boron tribromide gives the corresponding 7,8-dihydroxy substituted benzazepines. Another method for preparing the important N-methyl compounds is converting the 3-hydrogen compound into the N-formyl congener then reducing with lithium aluminum hydride, a two step reaction sequence.

The dialkanoyloxy derivatives such as the important 7,8-diacetoxy compounds can also be prepared by direct O-acylation of the dihydroxy compound having the N-position blocked by protonation such as using the 6-halo-7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrobromide in trifluoroacetic acid at ambient temperature with the anhydride or halide. The N or 3-lower alkanoyl congeners in the dihydroxy series are prepared conveniently by N-acylating the methoxy or methylenedioxy derivative followed by splitting the protective group with boron tribromide or chloride. Also direct N-alkanoylation of the dihydroxy compounds is possible under controlled conditions and quantities of reactants as known to the art. As noted in the illustrative examples any undesired O-acylation may necessitate a mild hydrolysis treatment.

The intermediates of Formula III above are conveniently prepared by heating equimolar amounts of an epoxyethylthiophene or furan with a 3,4-dialkoxyphenethylamine which is either known or prepared by methods known to the art, each appropriately substituted, either alone or in an inert organic solvent such as tetrahydrofuran. Preferably the heating is effected on a steam bath or at reflux temperature for from 12 to 24 hours. The required ethylene oxide is

The reaction is run at ambient temperature such as at room temperature for convenient periods of time such as from 1-24 hours. Overnight at room temperature is a convenient laboratory time period. The solvent may be any inert organic solvent or an excess of an organic acid solvent in which the reactants are soluble for example trifluoroacetic acid, methylene chloride, trichloroethylene, chloroform or carbon tetrachloride. Also at least one equivalent of acid catalyst must be present such as trifluoroacetic acid, sulfuric acid, boron trifluoroethereate, etc. Certain 1-hydroxy or alkoxy benzazepines are known to the art such as G. Hazebroucq, Compt. Rend. 257, 923 (1963) [C.A. 59, 12759] or J. Likforman, Compt. Rend. 268, 2340 (1969) [C.A. 71, 61184]. However, the specific 1-hydroxy-7,8-dihydroxy-benzazepine starting materials used here are new and are prepared by methods disclosed in the examples.

The active dopaminergic compounds of this invention used herein stimulate peripheral dopamine receptors, for example they increase renal blood flow and have as an end result hypotensive activity. This renal vasodilator activity of the benzazepine compounds of Formula I is measured in an anesthetized dog. In this pharmacological procedure, a test compound is administered at progressively increasing (3-fold) infusion rates beginning at 0.1 mcg/kg/min up to 810 mcg/kg/min for 5 minutes each to anesthetized normotensive dogs and the following parameters are measured: renal artery blood flow, iliac artery blood flow, arterial blood pressure and heart rate. Results are reported as a percent change, increase or decrease, at time of peak response (from pre-drug controls), and for a significant effect renal blood flow (increase) and renal vascular resistance (decrease) should be approximately 10% or greater. The effect on renal vascular resistance can be calculated from any change in renal blood

flow and arterial blood pressure To confirm the mechanism of action, representative active renal vasodilator compounds are checked for blockade by bulbocapnine which is known to be a specific blocker of renal dopamine receptors. Representative of compounds of Formula I for example: 7,8-dihydroxy-1-(2'-thienyl)-2,3,4,5-tetrahydro-1H-3-benzazepine hydrobromide tested by i.v. infusion as described above produced a decrease of renal vascular resistance of 30% at 30 mcg/kg; 7,8-dimethoxy-1-(5'-methyl-2'-thienyl)-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride had an ED₁₅ of 2.3 mcg/kg; 7,8-dihydroxy-1-(3'-thienyl)-2,3,4,5-tetrahydro-1H-3-benzazepine hydrobromide had an ED₁₅ of 40; the 5-methyl-2-thienyl, 50. ED₁₅ therefore is the cumulative dose by infusion which produces a 15% decrease in renal

..... vascular resistance ($R = \frac{B.P. \text{ in mm/hg}}{B.F. \text{ ml/min}}$).

..... In addition to the renal vasodilator activity via a
..... dopaminergic effect, certain benzazepine compounds of Formula I have
..... demonstrated weak diuretic activity. Such diuretic activity is
..... measured in the standard saline-loaded rat procedure. A test compound
..... is administered i.p. at doses of from 10 to 40 mg/kg and the parameters
..... measured are urine volume (hourly for three hours) plus sodium and
..... potassium ion concentrations. Also conventional diuretic tests in the
..... dog may be used. 7,8-Dihydroxy-1-(2'-thienyl)-2,3,4,5-tetrahydro-1H-
..... 3-benzazepine hydrobromide tested in the phosphate mannitol dog produced
..... a significant increase in renal plasma flow and natriuresis at a dose
..... as low as 10 and 20 µg/kg/min i.v. Similar results were obtained at
..... oral doses of 20 mg/kg.

The benzazepine compounds of Formula I also have some anti-parkinsonism activity due to central dopaminergic activity as demonstrated by employing a modified standard animal pharmacological test procedure reported by Ungerstedt et al., in Brain Research 24, 1970,

1 485-493. This procedure is based on a drug induced rotation of
rats having extensive unilateral lesions of the substantia nigra.
Briefly, the test comprises the quantitative recording of
rotational behavior in rats in which 6-hydroxydopamine lesions of
5 the nigrostriatal dopamine system have been produced. A unilateral
brain lesion in the left substantia nigra causes the dopamine
receptor in the left caudate to become hypersensitive following
the resulting degeneration of the nigral cell bodies. These lesions
destroy the source of the neurotransmitter dopamine in the caudate
0 but leave the caudate cell bodies and their dopamine receptors intact.
Activation of these receptors by drugs which produce contralateral
rotation, with respect to the lesioned side of the brain, is used as
a measure of central dopaminergic activity of the drug.

Compounds which are known to be clinically effective in
5 controlling parkinsonism, such as, for example, L-dopa and apomorphine,
are also effective in the rat turning model. These compounds directly
activate the dopamine receptors and cause contralateral rotation of the
lesioned rat.

Rotational activity is defined as the ability of a compound
to produce 500 contralateral rotations during a two-hour period after
administration, usually intraperitoneally. The dose corresponding to
500 contralateral rotation per two hours is obtained and assigned as the
KD₅₀₀ value.

Once again representative compounds of Formula I, 7,8-dihydroxy-
1-(2'-thienyl)-2,3,4,5-tetrahydro-1H-3-benzazepine hydrobromide, the
3-thienyl and the 5'-methyl-5'-thienyl congeners when tested as described
above in rats produced activity, i.p. at 5.5 (ED₅₀₀), 5 (active) and
1.5 (ED₅₀₀) mg/kg respectively. Further the compounds have a low
potential for inducing emesis or stereotyped behavior at doses which are
effective in the rat turning model.

The pharmaceutical compositions of this invention having dopaminergic activity are prepared in conventional dosage unit forms by incorporating a compound of Formula I, an isomer or a pharmaceutically acceptable addition of salt thereof, with a nontoxic pharmaceutical carrier according to accepted procedures in a nontoxic amount sufficient to produce the desired pharmacodynamic activity in a subject, animal or human. Preferably the compositions will contain the active ingredient in an active but nontoxic amount selected from about 25 mg to about 500 mg of active ingredient per dosage unit but this quantity depends on the specific biological activity desired and the conditions of patient. Generally speaking lower doses are needed to stimulate central dopamine receptors than peripheral receptors. The dosage units are given from 1-5 times daily.

.... The pharmaceutical carrier employed may be, for example, .. either a solid or liquid. Exemplary of solid carriers are lactose, .. terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium .. stearate, stearic acid, and the like. Exemplary of liquid carriers .. are syrup, peanut oil, olive oil, water and the like. Similarly the carrier or diluent may include any time delay material well known to .. the art, such as glyceryl monostearate or glyceryl distearate alone .. or with a wax.

.. A wide variety of pharmaceutical forms can be employed.

Thus, if a solid carrier for oral administration is used the .. preparation can be tableted, placed in a hard gelatin capsule in .. powder or pellet form, or in the form of a troche or lozenge. The .. amount of solid carrier will vary widely but preferably will be from about 25 mg to about 1 g. If a liquid carrier is used, the preparation will be in the form of a syrup, emulsion, soft gelatin capsule, sterile injectable liquid such as an ampul, or an aqueous or nonaqueous liquid suspension.

The pharmaceutical preparations are made following the conventional techniques of the pharmaceutical chemist involving mixing, granulating and compressing when necessary, or variously mixing and dissolving the ingredients as appropriate to give the desired end product.

The method of producing dopaminergic activity in accordance with this invention comprises administering internally to a subject in need of such activity a compound of Formula I or a pharmaceutically acceptable acid addition salt thereof, usually combined with a pharmaceutical carrier, in a nontoxic amount sufficient to produce said activity as described above. The route of administration may be any route which effectively transports the active compound to the dopamine receptors which are to be stimulated such as orally or parenterally, the oral route being preferred. Advantageously, equal doses will be administered several times such as two or three times a day with the daily dosage regimen being selected from about 50 mg to about 2 g. When the method described above is carried out hypotensive, diuretic or antiparkinsonism activity is produced with a minimum of side effects.

The following examples are designed solely to illustrate the preparation and use of the compounds of this invention. The temperatures are Centigrade. Other variations of these examples will be obvious to those skilled in the art.

EXAMPLE 1

4.84 Grams of sodium hydride (57% of mineral oil dispersion), after being washed with hexane to remove the oil, was stirred in 70 ml of dry dimethylsulfoxide and heated to 65-68° under argon for 1 hour. At this point a greenish clear solution resulted. The heating source was removed and 75 ml of dried tetrahydrofuran was then added. The resulting solution was cooled to 5° by means of a methanol-ice bath,

and 19 g (93 μ moles) of trimethylsulfonium iodide in 100 ml dry dimethylsulfoxide was added in about 5 minutes. The reaction mixture was stirred for another 5 minutes after complete addition.

A solution of 10.4 grams (93 μ moles) of 2-thiophenecarboxaldehyde in 120 ml of tetrahydrofuran was added to a moderate rate while keeping the reaction mixture at 0° to -5°. The mixture was stirred for another 5 minutes after complete addition and at room temperature for 1 hour, the mixture was diluted with 500 ml of ice water and extracted four times with ether. The combined extracts were washed with saturated brine solution and dried. Removal of the drying agent and solvent gave 10.1 of crude 2-epoxyethylthiophene (yellowish liquid), which was distilled under vacuum to give 8.1 g (69%) of light yellow liquid (b.p. 0.15 mm, 43-5°).

A mixture of 11.6 g (64 μ moles) of homoveratrylamine and 8.1 g (64 μ moles) of 2-epoxyethylthiophene was heated with stirring and under argon at 100° overnight. The reaction mixture was cooled to room temperature and was chromatographed in a silica column (700 g) and eluted with benzene-ethyl acetate gradient. The desired product and its isomer were thus separated. After recrystallization from ethyl acetate/hexane, 3.6 g (18.4%) of pure N-(β -hydroxy- β -2-thienyl) ethyl homoveratrylamine was obtained (m.p. 102°).



Calculated: 62.51% C; 6.89% H; 4.56% N

Found: 62.36% C; 6.69% H; 4.51% N


3.6 Grams (11.8 μ moles) of N-(β -hydroxy- β -2-thienyl)-ethylhomoveratrylamine was dissolved in a mixture of 36 ml of acetic acid and 18 ml of conc. hydrochloric acid. The resulting solution was heated at reflux for 3 hours. The reaction mixture was evaporated under reduced pressure to a brown residue which was then suspended in 5% sodium carbonate solution and thoroughly extracted with ethyl acetate.

The extracts were combined, washed once with saturated brine, and dried. Removal of the drying agent and solvent gave 3.3 g of a thick oily residue (96% yield); 1-(2'-thienyl)-7,8-dimethoxy-2,3,4,5-tetrahydro-1H-3-benzazepine.

The procedure outlined above is the basic method for preparing the compounds of this invention. Others may be prepared by substituting equivalent amounts of the appropriate heterocyclic carboxaldehyde or ethylenepoxide for the 2'-thienyl reactants in the reactions detailed.

This compound is also prepared by treatment of 8.9 g (40 μ moles) of 1-hydroxy-7,8-dimethoxy-2,3,4,5-tetrahydro-1H-3-benzazepine with 5 ml of thiophene in 45 ml of trifluoroacetic acid under argon at room temperature overnight. After stripping off the volatiles, the residue was dissolved in 250 ml 3N hydrochloric acid. This acidic solution was thoroughly washed with ether, basified with conc. ammonium, extracted 3 times with ethyl acetate. The extracts were combined, washed once with saturated brine and dried anhydrous potassium carbonate. Removal of drying agent and solvent gave 9.2 of the desired base as an oily residue (81%).

A sample of this oily residue was dissolved in ethyl ether and ethereal hydrogen bromide was added. An off-white precipitate was obtained. This was recrystallized from methanol-ethyl acetate to give the pure hydrobromide (m.p. 215°).




Calculated: 51.90% C 5.44% H, 3.78% N

Found: 52.10% C; 5.58% H; 3.65% N

1 EXAMPLE 2

3.5 Grams (12 mmoles) of 1-(2'-thienyl)-7,8-dimethoxy-
2,3,4,5-tetrahydro-1H-3-benzazepine dissolved in 60 ml of methylene
chloride was cooled to -12° by means of a methanol-ice bath, and
5 6 ml (62 mmoles) boron tribromide was added dropwise. The resulting
solution was stirred at room temperature for 1.5 hours and was then
evaporated to a brown residue under reduced pressure. The residue
was cooled in ice and treated slowly with methanol. The methanol
was evaporated at room temperature under reduced pressure. The
10 residue was treated with methanol again and stripped under reduced
pressure in a 50° hot-water bath. This treatment was repeated 3
times. The final residue was either chromatographed on a silica
column eluted with 9:1 chloroform/methanol or dissolved in water,
any undissolved material filtered off and the aqueous filtrate
lyophilized to give pure 1-(2'-thienyl)-7,8-dihydroxy-2,3,4,5-
15 tetrahydro-3-1H-benzazepine hydrobromide salt, m.p. 239-40° (dec),
ca. 70% yield.



Calculated: 49.13% C; 4.71% H; 4.09% N; 9.37% S

10 Found: 48.91% C; 4.59% H; 4.10% N; 9.10% S

The free base is obtained by dissolving the salt in a
minimum amount of water and slowly adding 5% sodium bicarbonate
solution until the base separates.


EXAMPLE 3

3-Thiophenecarboxaldehyde was prepared by following a
literature procedure (Org. Syn. Coll. Vol. IV pp. 918-9) from
3-thienyl bromide which in turn was prepared also by following a
literature procedure (Org. Syn. Coll. Vol. IV, pp 921-3) from
3-methylthiophene.

1 9.2 Grams (30 mmoles) N-(8-hydroxy-8-3-thienyl)-
ethylhomoveratrylamine was dissolved in 92 ml of acetic acid and
46 ml of conc. hydrochloric acid. The mixture was heated at reflux
for 3 hours, stripped under reduced pressure to a brown residue,
5 which was then treated with 5% carbonate solution and thoroughly
extracted with ethyl acetate. The organic extracts were combined
and washed twice with brine and dried over anhydrous sodium
sulfate. Removal of drying agent and solvent gave 8.7 g of thick
oily residue (99% yield), 1-(3'-thienyl)-7,8-dimethoxy-2,3,4,5-
10 tetrahydro-1H-3-benzazepine.

A sample of this free base was dissolved in methanol and
ethereal hydrogen chloride was added until acidic. This acidic
solution was evaporated to dryness. Recrystallization of the
residue from methanol-ethyl acetate gave the pure hydrochloride
salt (m.p. 178°).

15 5.25 Grams (18 mmoles) of 1-(3'-thienyl)-7,8-dimethoxy-
2,3,4,5-tetrahydro-3-1H-benzazepine dissolved in 90 ml of methylene
chloride was cooled to -12° by means of a methanol/ice bath and
9 ml of boron tribromide (93 mmoles) was added dropwise. The
resulting solution was allowed to warm to room temperature for
1.5 hours. The solvent was stripped off to give a brown residue
which was chilled and carefully treated with methanol. The
methanol was evaporated under reduced pressure and the resulting
residue was again treated with methanol and stripped at 50°. This
process was repeated 3 times and 4.2 g of crude 1-(3'-thienyl)-7,
8-dihydroxy-2,3,4,5-tetrahydro-3-1H-benzazepine hydrobromide was
25 obtained. This was further purified by chromatography over silica,
eluted with 9:1 chloroform:methanol, and dissolved in water,
charcoaled, and filtered. Lyophilization of the filtrate gave 2.8 g
of buff colored amorphous powder (m.p. 254-6° dec.).



Calculated: 46.10% C; 5.11% H; 3.84% N; 8.73% S

Found: 45.84% C; 4.89% H; 3.68% N; 8.39% S

EXAMPLE 4

To 181 g (1 mole) of homoveratrylamine in 1 l. of ethanol was added 117 g (1.1 mole) of benzaldehyde. The mixture was stirred at room temperature for 15 minutes. A solution of 100 g of potassium borohydride in 500 ml cold water was then slowly added while the solution was kept at near room temperature by external cooling. After complete addition of the hydride solution, the reaction mixture was stirred for 5 hours and then chilled and acidified with 6N hydrochloric acid. Further chilling to 0° precipitated the N-benzyl homoveratrylamine hydrochloride salt which was collected by filtration. The crude product recrystallized from ethanol (m.p. 204-6°).

44 Grams (0.143 moles) of the N-benzylhomoveratrylamine hydrochloride salt was suspended in 440 ml of dry dimethylformamide. To this were added 100 g (0.725 moles) of powdered anhydrous potassium carbonate and 29 g (0.17 mole) of bromoacetaldehyde dimethyl acetal. The reaction mixture was heated at reflux with stirring for 20-24 hours under argon. The salts were then removed by filtration, and the filtrate was evaporated under reduced pressure to yield a dark brown oil. This was dissolved in a water-ethyl acetate mixture and the layers were separated. The water layer was thoroughly extracted with ethyl acetate. The combined organic layers were back washed once with brine solution, dried, and the solvent evaporated to give 46 g of crude product (brown syrup 90% yield). Chromatography gave a 64% yield of pure N-benzyl-N-(β-3,4-dimethoxyphenyl)ethylamino-acetaldehyde dimethyl acetal.

1 The dimethyl acetal (24 g) was dissolved in 240 ml of
conc. HCl:HOAc:H₂O (3:2:1 ratio) and allowed to stand overnight at
room temperature. It was then poured into 1 l. ice-water, basified
to pH = 8 by addition of conc. ammonia, and extracted with ethyl
5 acetate. The extracts were combined, back washed once with
saturated brine and dried over anhydrous sodium sulfate. Removal
of the drying agent and solvent gave 19.5 g of crude product
(92% yield).

Chromatography over a silica column gave pure N-benzyl-
0 1-hydroxy-7,8-dimethoxy-2,3,4,5-tetrahydro-1H-3-benzazepine in a
51% yield. The oily product could be crystallized from ethyl
acetate-hexane.

The "dimethylacetal" reaction described in detail above
is another general method which may be used to prepare various
1-hydroxybenzazepine intermediates of this invention using as starting
materials various substituted N-lower alkyl or phenalkylhomoveratry-
lamines especially the N-methyl, N-benzyl or N-phenethylhomoveratry-
lamines. The reaction apparently does not go on the N-H amines.
The N-benzyl compounds are of most general use because the protective
benzyl group can be readily removed as described hereafter.


1.1 Grams of the pure N-benzyl-1-hydroxyl benzazepine was
dissolved in 50 ml methanol and 220 mg 10% Pd/C on charcoal
wetted with butanol was added. The solution was shaken for 4 hours
under hydrogen at 40 psi. The catalyst was removed by filtration and
the filtrate was evaporated under reduced pressure to give a slightly
yellow syrup which was crystallized from ethyl acetate. Recrystallization
from acetonitrile (m.p. 153-4°) gave pure 1-hydroxy-7,8-
dimethoxy-2,3,4,5-tetrahydro-1H-3-benzazepine a key new intermediate.

2,3,4,5-tetrahydro-1H-3-benzazepine and 2.5 ml of 2-methyl-thiophene were dissolved in 45 ml trifluoroacetic acid. The reaction mixture was allowed to stand at room temperature overnight, then evaporated under reduced pressure to an oily residue which was dissolved in 250 ml of 3N hydrochloric acid. The acidic solution was thoroughly washed with ether, then basified with conc. ammonia, and finally extracted with ethyl acetate. The organic extracts were combined, washed with saturated brine, and dried over anhydrous sodium sulfate. Removal of drying agent and solvent gave 10.1 g. of 1-(5'-methyl-2'-thienyl)-7,8-dimethoxy-2,3,4,5-tetrahydro-1H-3-benzazepine as an oil (83.3%); m.p. (HCl) 227-228°. In the same way 1-(2'-thienyl)-7,8-dimethoxy-2,3,4,5-tetrahydro-1H-3-benzazepine, and 1-(2'-furyl)-7,8-dimethoxy-2,3,4,5-tetrahydro-1H-3-benzazepine are made using thiophene, 2-bromothiophene and furan.

EXAMPLE 5

4.6 Grams (15 mmoles) of 1-(5'-methyl-2'-thienyl)-7,8-dimethoxy-2,3,4,5-tetrahydro-1H-3-benzazepine was dissolved in 45 ml methylene chloride under argon; the solution was cooled to -12° by a methanol-ice bath, and 78 ml of boron tribromide in methylene chloride (1 g/5 ml) was slowly added. The dark brown solution which resulted was allowed to warm to room temperature for one hour, and evaporated under reduced pressure to a brown residue. This was chilled to 0°, methanol was slowly added and then evaporated. This was repeated 5 times and the resulting dark brown gum was dissolved in water and filtered through a pad of "Supercel". The filtrate was lyophilized to give a yellowish powder which was further purified by chromatography on silica gel. Elution with 9:1 chloroform-methanol gave 2.4 g of pure 1-(5'-methyl-2'-thienyl)-7,8-dihydroxy-2,3,4,5-tetrahydro-1H-3-benzazepine

1 hydrobromide (m.p. 169° dec.).



Calculated: 48.72% C; 4.91% H; 3.78% N

Found: 48.86% C; 4.84% H; 3.87% N

5 In similar manner the 7,8-dihydroxy-1-(2'-thienyl), (5'-bromo-2'-thienyl) and (2'-furyl) congeners are made from the 7,8-dimethoxy compounds of Example 4.

EXAMPLE 6

3 A mixture of 10.2 g (0.056 mole) of homoveratrylamine and 5.9 g (0.053 mole) of 2-epoxyethylfuran were mixed and heated on the steam bath overnight and worked up as in Example 1 to give N-(β-hydroxy-8-2'-furyl)ethylhomoveratrylamine, as a crystalline solid which was recrystallized from ethyl acetate-petroleum ether (m.p. 90°).

... The furylaminoalcohol (2.9 g) was cyclized in 30 ml of
; trifluoroacetic acid at room temperature overnight. The black mixture
... was poured into 20 ml of ammonium hydroxide, 300 ml of ice and 40 ml
... of ethyl acetate, and more ammonia was added to pH 9. The combined
... organic layer and subsequent extracts were washed with brine and dried
... over anhydrous sodium sulfate. Evaporation of the solvent in vacuo
... after removal of the drying agent gave 2.51 g of oily product,
... 1-(2'-furyl)-7,8-dimethoxy-2,3,4,5-tetrahydro-1H-3-benzazepine. This
... material is identical to the same product prepared by catalytic hydro-
... genation of the N-benzyl derivative (Examples 7 and 8) using palladium
... on charcoal in methanol at 50°.


EXAMPLE 7

... A solution of 20.1 g (64 mmole) of 1-hydroxy-N-benzyl-
... 7,8-dimethoxy-2,3,4,5-tetrahydro-1H-3-benzazepine in 130 ml of
... methylene chloride was treated with 14 g (0.2 mole) of furan and
... 16 ml of ethereal boron trifluoride. After standing overnight at
... room temperature the reaction mixture was stirred with concentrated

1 ammonium hydroxide and ice. The methylene chloride phase was separated
and extracted with 1M phosphoric acid. The acid extracts were
neutralized and extracted with ethyl acetate. The dried extracts
were evaporated to 19.8 g of crude product [1-(2'-furyl)-3-benzyl-
5 7,8-dimethoxy-2,3,4,5-tetrahydro-1H-3-benzazepine] which was purified
by chromatography over silica.

EXAMPLE 8

The N-benzyl product (14.2 g, 0.12 mole), prepared as in
Example 7, in methylene chloride was reacted with 145 ml of boron
10 tribromide-methylene chloride (1 g/5 ml) at room temperature for
1.25 hours. The desired 1-(2'-furyl)-3-benzyl-7,8-dihydroxy-
2,3,4,5-tetrahydro-1H-3-benzazepine was isolated as described above.
This compound was debenzylated by hydrogenolysis as described in
Example 6 to give 1-(2'-furyl)-3-benzyl-7,8-dihydroxy-2,3,4,5-
15 tetrahydro-1H-3-benzazepine as described above. This
compound was debenzylated by hydrogenolysis as described in
Example 6 to give 1-(2'-furyl)-7,8-dihydroxy-2,3,4,5-tetrahydro-
1H-3-benzazepine. It's hemi-fumarate salt was prepared in methanol
and was recrystallized from water (m.p. 267° dec.).



Calculated: 62.43% C; 5.73% H; 4.56% N

Found: 62.78% C; 6.14% H; 4.52% N

EXAMPLE 9

Three solutions each with 0.31 g (1 mmole) of 1-hydroxy-
3-benzyl-7,8-dimethoxy-2,3,4,5-tetrahydro-1H-3-benzazepine in 2 ml
of methylene chloride containing boron trifluoride etherate were
respectively reacted with an excess of furan, 2-methylfuran and
2-cyanomethylfuran at room temperature overnight. Each was quenched
in ammonia solution, isolated and passed over silica gel. This layer
chromatography on silica gel using cyclohexane-ethyl acetate (7:3)

1 gave R_f values of 0.68, 0.70 and 0.43 respectively with the starting material at 0.14. These are the 2'-furyl, 5'-methyl-2'-furyl and 5'-cyanomethyl-2'-furyl congeners which can be optionally debenzylated and demethylated as described to give 1-(2'-furyl)-7,8-dihydroxy-2,3,4,5-tetrahydro-1H-3-benzazepine, its methylfuryl and its cyanomethylfuryl congeners.

Repeating this reaction with 1-hydroxy-3-methyl-7,8-dimethoxy-2,3,4,5-tetrahydro-1H-3-benzazepine (prepared from N-methylhomoveratrylamine as in Example 4 and 2-methylthiophene gives 1-(5'-methyl-2'-thienyl)-3-methyl-7,8-dimethoxy-2,3,4,5-tetrahydro-1H-3-benzazepine. Demethylation as described above gives 1-(5'-methyl-2'-thienyl)-3-methyl-7,8-dihydroxy-2,3,4,5-tetrahydro-1H-3-benzazepine hydrobromide.

EXAMPLE 10

A mixture of 7.9 g (25.2 mmoles) of 1-hydroxy-3-benzyl-7,8-dimethoxy-2,3,4,5-tetrahydro-1H-3-benzazepine, 6.35 g (50.4 mmoles) of methyl furoate and 6.2 ml (50.4 mmoles) of boron trifluoride etherate was reacted at room temperature for 1.5 hours. Another 3.1 ml of trifluoride was added followed by standing at room temperature overnight. The product, 1-(5'-carbomethoxy-2'-furyl)-benzyl-7,8-dimethoxy-2,3,4,5-tetrahydro-1H-3-benzazepine was isolated and purified by methods similar to those of the previous examples. This material was demethylated to the 7,8-dihydroxy compound and debenzylated as described above to give 1-(5'-carbomethoxy-2'-furyl)-7,8-dihydroxy-2,3,4,5-tetrahydro-1H-3-benzazepine hemifumarate hydrate, m.p. 198-200° (dec.).

EXAMPLE 11

Reacting 2-chloro-3,4-dimethoxyphenylethylamine, 2-fluoro-3,4-dimethoxyphenylethylamine or 2-trifluoromethyl-3,4-dimethoxyphenylethylamine (prepared via 2-trifluoromethyl-3,4-dimethoxycoluene) in a stoichiometric quantities with 2-epoxyethylthiophene as in Example 1

gives 2-chloro-1-(2'-thienyl)-7,8-dihydroxy-2,3,4,5-tetrahydro-1H-3-benzazepine, 6-fluoro-1-(2'-thienyl)-7,8-dihydroxy-2,3,4,5-tetrahydro-1H-3-benzazepine and 6-trifluoromethyl-1-(2'-thienyl)-7,8-dihydroxy-2,3,4,5-tetrahydro-1H-3-benzazepine via their 7,8-dimethyl ethers.

EXAMPLE 12

A mixture of 4.5 g of 6-chloro-7,8-dimethoxy-1-(2'-thienyl)-2,3,4,5-tetrahydro-1H-3-benzazepine, 0.02 ml of n-butyl bromide and 0.02 mol of potassium hydroxide is dissolved in 120 ml of dry methanol and refluxed for 48 hours. The reaction mixture is evaporated to dryness, taken up in ethyl acetate and filtered to remove inorganic salts. The filtrate is washed with water, dried and evaporated to give 3-n-butyl-6-chloro-7,8-dimethoxy-1-(2'-thienyl)-2,3,4,5-tetrahydro-1H-3-benzazepine.

The 3-n-butyl benzazepine (0.01 mol) is dissolved in 120 ml of dry methylene chloride and 0.032 mol of boron tribromide is added dropwise at -10°. The solution is warmed to room temperature and stirred for two hours. The excess boron tribromide is destroyed with methanol added dropwise with ice-cooling. The cold solution is refluxed on the steam bath to remove hydrogen bromide and evaporated. The residue is treated with brine at reflux for 2 hours to yield 3-n-butyl-6-chloro-7,8-dihydroxy-1-(2'-thienyl)-2,3,4,5-tetrahydro-1H-3-benzazepine hydrobromide.

Using N-alkylation procedures described above but using 7,8-dimethoxy-1-(5'-methyl-2'-thienyl)-2,3,4,5-tetrahydro-1H-3-benzazepine as a model compound the N-allyl, N-phenethyl, N-butyl, N-4-nyl or N-2,2-dimethylallyl derivatives are prepared. Hydrolysis of the methoxy groups as described gives the active 7,8-dihydroxy compounds.

EXAMPLE 13

A 3.9 g sample of 7,8-dihydroxy-1-(3'-thienyl)-2,3,4,5-tetrahydro-1H-3-benzazepine is slurried in 25 ml of acetone and 0.7 g

1 (0.016 mol, 10% excess) of ethylene oxide is added. The mixture is placed in a pressure bottle and stirred at ambient temperature for about 40 hours. The reaction mixture is then heated to 60-80° for 30 minutes, cooled and filtered. Concentration of the filtrate gives 5 a solid which is taken up in ethyl acetate and reprecipitated with ether. The solid thus obtained is dissolved in ethanol and treated with ethereal hydrogen chloride to give 7,8-dihydroxy-3-(2-hydroxy-ethyl)-1-(3'-thienyl)-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride.

EXAMPLE 14

10 A 4.0 g sample of 3-benzyl-7,8-dihydroxy-1-(2'-thienyl)-2,3,4,5-tetrahydro-1H-3-benzazepine (prepared from the 3-unsubstituted benzazepine by reaction with benzyl bromide in the presence of potassium carbonate) is dissolved in 50 ml of acetic anhydride and the solution is heated on a steam bath for one hour. The reaction mixture is cooled, ice-water is added and the solution is evaporated to dryness. The residue is triturated with ethyl acetate, the solution washed with 45 water, dried and the solvent removed in vacuo to leave an oil. The latter is dissolved in ether and ethereal hydrogen chloride is added to precipitate 3-benzyl-7,8-diacetoxy-1-(2'-thienyl)-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride.

20 7,8-dihydroxy-1-(2'-thienyl)-2,3,4,5-tetrahydro-1H-3-benzazepine hydrobromide (10 g) is dissolved in trifluoroacetic acid and reacted with a stoichiometric amount of acetyl bromide at room temperature for 1-2 hours. The reaction mixture is evaporated and the residue is triturated in ether-i-propanol to give the desired diacetoxy derivative.

25 Substituting other alkanoyl anhydrides or chlorides gives various 7,8-alkanoyl derivatives such as the diacetoxy derivatives of 2'-furyl, 5'-methyl-2'-furyl, 5'-cyanomethyl, 3'-thienyl, 5'-methyl-2'-thienyl, and 5'-bromo-2'-thienyl compounds.

7,8-Dihydroxy-1-(2'-thienyl)-2,3,4,5-tetrahydro-1H-3-

benzazepine (5 g) is suspended in 500 cc of benzene. Trifluoroacetic anhydride (15 g) is added dropwise rapidly. The solution is stirred an additional hour and the volatiles stripped off, leaving the N,O,O-tris-trifluoroacetyl derivative. This is added directly to 500 cc of methanol and hydrogen chloride gas bubbled in for a few minutes. The reaction is stirred for 2 hours and then the solvent stripped off, leaving 7,8-dihydroxy-1-(2'-thienyl)-3-trifluoroacetyl-2,3,4,5-tetrahydro-1H-3-benzazepine.

EXAMPLE 16

Dry dimethylformamide (50 ml) is deoxygenated four times by pulling a vacuum and refilling the vacuated flask with argon. 7,8-Dihydroxy-1-(2'-thienyl)-3-trifluoroacetyl-2,3,4,5-tetrahydro-1H-3-benzazepine (5 g) is added and dissolved as the solution is deoxygenated once more. Methylene bromide (5.3 g) potassium carbonate (5 g) and cupric oxide (0.13 g) are added and the solution is deoxygenated a final time. The reaction is heated at 150° under argon for 2 hours.

It is worked up by pouring into 2 l. of ice water while stirring. The aqueous suspension is extracted four times with 300-400 cc ether, and the ether is back extracted three times with 1.5 l. water. The ether is dried and evaporated. The residue is dissolved in chloroform and chromatographed on silica gel to give 7,8-methylenedioxy-1-(2'-thienyl)-3-trifluoroacetyl-2,3,4,5-tetrahydro-1H-3-benzazepine.

EXAMPLE 17

A suspension of 7,8-dihydroxy-1-(2'-thienyl)-2,3,4,5-tetrahydro-1H-3-benzazepine hydrobromide (3.4 g) in methanol (40 ml) is reacted with 2.5 g of 2,3-dichloro-5,6-dicyano-1,4-benzoquinone in methanol at 0° for 1 hour. The 1-(2'-thienyl)-2,3,4,5-tetrahydro-1H-3-benzazepine-7,8-dione hydrobromide was collected by filtration and washed with ether. The dione hydrobromide salt is added to an excess

1. of methyl mercaptan in methanol. After 1 hour the solution is evaporated to give a residue of the 6-methylthio and 8-methylthio isomers. Separation over a silica gel column gives 6-methylthio-1-(2'-thienyl)-2,3,4,5-tetrahydro-1H-3-benzazepine hydrobromide salt.

Similarly 6-methylthio-3'-thienyl and 2'-furyl congeners are made.

EXAMPLE 18

5.5 Grams (19 mm) of 7,8-dimethoxy-1-(3'-methyl-2'-thienyl)-2,3,4,5-tetrahydro-1H-3-benzazepine was dissolved in 120 ml of ethylformate and was heated at reflux for 24 hours. After addition of 50 ml of ethyl ether, the reaction mixture was washed with 3 x 30 ml of 3N hydrochloric acid, 2 x 20 ml of 5% sodium bicarbonate, and then brine. After drying over sodium sulfate and removal of the drying agent, the solvent was evaporated to give 4.8 g of the oily N-formyl derivative.

EXAMPLE 19

To 120 ml of ethyl ether under argon, 2.15 g of lithium aluminum hydride was added followed by addition of 4.7 g (14.2 mmoles) of the N-formyl derivative in 80 ml of benzene. The resulting suspension was gently refluxed for 5 hours. It was then cooled and the excess hydride was decomposed by addition of 6 ml of methanol in 25 ml ether, 2.15 ml of water, 2.15 ml of 10% alkali, and 6.45 ml of water, in that sequence. The solid formed was removed by filtration. The filtrate was evaporated to an oil which was taken up in ethyl acetate and thoroughly extracted with 3N hydrochloric acid. The acidic extracts were combined, washed with ether, basified to pH 8, and thoroughly extracted with ethyl acetate. The organic extracts were combined and dried over anhydrous sodium carbonate. Removal of the drying agent and solvent gave 3.8 g of 1-(3'-methyl-2'-thienyl)-3-methyl-7,8-dimethoxy-2,3,4,5-tetrahydro-1H-3-benzazepine.

This was dissolved in methanol and ethereal hydrogen chloride was added. The solution was stripped to dryness under reduced pressure to give 7,8-dimethoxy-1-(3'-methyl-2'-thienyl)-3-methyl-2,3,4,5-tetrahydro-

1H-3-benzazepine which was recrystallized from methanol-ethyl acetate hydrochloride (m.p. 227-8°).

Substituting the 1-(2'-thienyl), 1-(3'-thienyl) or 1-(2'-furyl) congeners in the procedures of Examples 19-20 with obvious variations gives 7,8-dimethoxy-1-(2'-thienyl)-3-methyl-3,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride, 7,8-dimethoxy-1-(3'-thienyl)-3-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride or 7,8-dimethoxy-1-(2'-furyl)-3-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine hemifumarate. Splitting the ethers as described above gives the three dihydroxy congeners.

EXAMPLE 20

Treatment of the dione hydrobromide salt with anhydrous hydrogen bromide in methanol or with diluted hydrobromic acid, gives 6-bromo-1-(2'-thienyl)-2,3,4,5-tetrahydro-1H-3-benzazepine hydrobromide salt. Similarly the 6-bromo-1-(5'-methyl-2'-thienyl), 6-bromo-1-(2'-furyl), 6-bromo-3'-thienyl analogs are prepared.

<u>Ingredients</u>	<u>Mg. per Capsule</u>
7,8-Dihydroxy-1-(5'-methyl-2'-thienyl)- 2,3,4,5-tetrahydro-1H-3-benzazepine (as an acid addition salt)	125 (free base)
Magnesium stearate	2
Lactose	200

The above ingredients are thoroughly mixed and placed into hard gelatin capsules. Such capsules are administered orally to subjects in need of treatment from 1-5 times daily to induce dopaminergic activity.

EXAMPLE 21

<u>Ingredients</u>	<u>Mg. per Tablet</u>
-Dihydroxy-1-(2'-thienyl)-2,3,4,5-tetrahydro-1H-3-benzazepine (as an addition salt)	200 (free base)
1 starch	30
vinyl pyrrolidone	12
1 starch	16
cesium stearate	3

first two ingredients are thoroughly mixed and granulated. The granules obtained are dried, mixed with the remaining corn starch and cesium stearate, and compressed into tablets.

The capsules or tablets thusly prepared are administered orally to an animal or human requiring stimulation of either peripheral or central dopamine receptors to induce hypotension or to treat the symptoms of Parkinson's disease within the dose ranges set forth hereinabove. Similarly other compounds of Formula I and the illustrative examples can be formulated in the same manner to give pharmaceutical compositions useful in the methods of this invention based on the chemical characteristics and relative biological activity using the test methods outlined.

A subgeneric group of compounds within the illustrative generic group of Formula I are those in which:

R is phenethyl, benzyl, lower alkyl of 1-5 carbon atoms, hydroxyethyl or lower alkenyl of 3-5 carbon atoms;

R₁ is hydrogen, halo, trifluoromethyl, lower alkylthio, trifluoromethylthio, methyl or methoxy;

R₂ and R₃ are each hydrogen, lower alkyl of 1-5 carbon atoms, lower alkanoyl of 2-5 carbon atoms or, when taken together, methylene or ethylene;

R₄ is hydrogen, halo or methyl; and

X is -C- or -S-.

In this subgeneric group, particular compounds are those in which R is methyl or allyl; R₁ is hydrogen, chloro, bromo or methylthio; R₂ and R₃ are the same and are hydrogen, methyl or acetyl; R₄ is hydrogen or 5'-methyl; and X is -S-.

The compounds of the above subgeneric group have particularly useful hypotensive activity, producing arterial hypotension and concomitant bradycardia. This activity is demonstrated in anesthetized spontaneously hypertensive rats (SHR). In this pharmacological procedure, adult male SHR, weighing approximately 350-400 grams, are anesthetized with pentobarbital sodium (65 mg/kg, i.p.). The trachea is cannulated and the rats are allowed to respire spontaneously. Pulsatile arterial blood pressure is measured from a cannulated carotid artery using a Statham transducer (P23AA). Mean arterial blood pressure is calculated as diastolic blood pressure plus 1/3 pulse pressure. Cardiac rate is monitored by means of a cardiometer triggered by the systolic blood pressure pulse. Phasic arterial blood pressure and cardiac rate are recorded using a multichannel oscillograph. Drug solutions are administered through a cannulated tail vein. Approximately 10 minutes are allowed to elapse, following surgery, for equilibration of the preparation. After the equilibration period, a control tracing of the directly measure parameters is taken. Each rat then receives an initial dose of 1 mcg/kg of a test compound. Arterial blood pressure and cardiac rate responses are recorded and expressed as absolute change from the respective control value established immediately prior to the injection. This sequence is repeated at approximately 5-10 minute intervals, with increasing dose levels of the test compound, until each rat has received individual doses of 1, 3, 10, 30, 100, 300 and 1000 mcg/kg.

The following table sets forth mean arterial blood pressure and cardiac rate responses produced in the anesthetized SHR, according to the above described procedure, upon i.v. administration to 3 rats of 7,8-dimethoxy-3-methyl-1-(5'-methyl-2'-thienyl)-2,3,4,5-tetrahydro-1H-3-benzazepine as its hydrochloride salt (doses refer to mcg/kg of the free base).

Change in Mean Arterial Blood Pressure (mmHg)

1 mcg/kg	3 mcg/kg	10 mcg/kg	30 mcg/kg	100 mcg/kg	300 mcg/kg	1000 mcg/kg
+5.6±1.3	+10.0±1.1	+7.3±1.7	-21.6±11.3	-88.0±7.9	-75.0±7.2	-67.2±4.4


Change in Cardiac Rate (beats/minute)

1 mcg/kg	3 mcg/kg	10 mcg/kg	30 mcg/kg	100 mcg/kg	300 mcg/kg	1000 mcg/kg
-4.6±1.7	-1.0±1.5	-0.6±2.8	-73.6±25.4	-174±29.7	-144±30.8	-98±25.2

This compound therefore produced average maximum changes in arterial blood pressure of -88 mmHg and cardiac rate of -174 beats/minute with dose-related hypotension from 30-1000 mcg/kg and bradycardia over the entire dose range.

THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:

1. A compound of the formula:



in which:

R is hydrogen, benzyl, phenethyl, lower alkanoyl of 1-5 carbons, ~~lower alkyl of 1-5 carbons~~, hydroxyethyl or lower alkenyl of 3-5 carbons;

R₁ is hydrogen, halo, trifluoromethyl, methylthio, trifluoromethylthio, methyl or methoxy;

R₂ and R₃ are each hydrogen, lower alkyl of 1-5 carbons, lower alkanoyl of 2-5 carbons or, when taken together, methylene or ethylene;

R₄ is hydrogen, halo, cyanomethyl, methyl or carbomethoxy;
and

X is -O- or -S- ;

or the pharmaceutically acceptable nontoxic salts thereof.

2. The compound of claim 1 in which X is -S- and R is methyl.

3. The compound of claim 1 in which R is methyl, R₁ is hydrogen, R₂ and R₃ are both methyl, R₄ is hydrogen or methyl and X is -S-.



3747178

4. The compound of claim 3 in which R_1 is 5'-methyl, and X is -S- and the point of attachment for the thienyl ring is 2'.

5. The compound of claim 4 in which the salt form is the hydrochloride.

6. The compound of claim 1 in which R is methyl and R_1 , R_2 , R_3 and R_4 are hydrogen.


7. The compound of claim 6 in which a thienyl ring is attached at the 2'-position. _____

1 8. The compound of claim 6 in which the thienyl
ring is attached at the 3'-position.

9. The compound of claim 1 in which R is methyl and
X is -O-.

5 10. A pharmaceutical composition having dopaminergic
or antihypertensive activity comprising an effective therefor
and nontoxic quantity of a compound of claim 1 and a dosage
unit carrier therefor.

11. The method of preparing a compound of claim 1
comprising reacting a compound of the formula:



in which R is lower alkyl, benzyl or phenethyl, R₁ is hydrogen,
halo, trifluoromethyl, methylthio, trifluoromethylthio, methyl
or methoxy; and R₂ and R₃ are lower alkyl, and, when taken
together, methylene or ethylene; with a compound of the formula:



in which R₄ is hydrogen, halo, methyl, cyanomethyl or carbo-
methoxy in the presence of at least one equivalent of an acid
catalyst; followed by optional N-alkylation, O-dealkylation or
alkylation and salt formation by methods known to the art.

12. The method of claim 11 in which R is methyl, and
X is -S-.

13. The method of claim 11 in which R is methyl, R₁ is
hydrogen, R₂ and R₃ are methyl, R₄ is 5'-methyl, X is -S- and
the thienyl ring is attached at position 2'.

14. The method of claim 13 in which a nontoxic salt is formed.

15. The method of claim 14 in which the hydrochloride or methanesulfonate salt is formed.

DATED this 21 day of January 1981.

DAVIES & COLLISON

Patent Attorneys for

SMITHKLINE CORPORATION



ENGLISH ABSTRACT FOR SU1238732

1 / 1 WPAT - ©The Thomson Corp.

Derwent Accession :

1983-56711K [24]

CPI Accession :

C1983-055068

Title :

Alpha-2 antagonist compsn. contg. 3-benzazepine cpd. esp. for reducing intra-ocular pressure and blood pressure

Derwent Class :

B02

Patent Assignee :

(SMIK) SMITHKLINE BECKMAN CORP

Inventor :

DEMARINIS RM; HIEBLE JP; MATTHEWS WD

Nbr of Patents :

19

Nbr of Countries :

27

Patent Number :

EP--80779 A 19830608 DW1983-24 Eng 29p *

AP: 1982EP-0201507 19821129

JP58092616 A 19830602 DW1983-28 Jpn

AP: 1982JP-0201817 19821116

AU8290172 A 19820602 DW1983-29 Eng

AP: 1982AU-0090172 19821104

NO8203990 A 19830620 DW1983-31 Nor

AP: 1982NO-0003990 19821126

FI8203715 A 19830729 DW1983-36 Fin

AP: 1982FI-0003715 19821101

DK8204931 A 19830801 DW1983-37 Dan

AP: 1982DK-0004931 19821105

HUT027615 T 19831028 DW1983-49 Hun

PT--75838 A 19831207 DW1984-02 Por

AP: 1982PT-0075838 19821112

ZA8207887 A 19831018 DW1984-05 Eng

AP: 1982ZA-0007887 19821028

DD-205896 A 19840111 DW1984-19 Ger

AP: 1982DD-0245313 19821129

US4465677 A 19840814 DW1984-35 Eng

AP: 1982US-0398015 19820714

CS8208075 A 19840717 DW1984-40 Cze

ES8405769 A 19841001 DW1984-49 Spa

AP: 1982ES-0517697 19821126

RO--85262 A 19841030 DW1985-18 Rum

AP: 1982RO-0109135 19821125

EP--80779 B 19860716 DW1986-29 Eng

AP: 1982EP-0201507 19821129

DE3272044 G 19860821 DW1986-35 Ger

CA1214165 A 19861118 DW1986-51 Eng
AP: 1982CA-0414027 19821022

SU1238732 A 19860615 DW1987-05 Rus
AP: 1982SU-3513948 19821125

IL-67092 A 19870916 DW1987-47 Eng.
AP: 1982IL-0067092 19821027

Priority Number :

1982EP-0305361 19821008; 1981US-0325249 19811127; 1982US-0398015 19820714

Intl Patent Class :

C07D-223/16; A61K-031/33; A61K-031/55; A61P-025/02; A61P-027/02;
A61P-027/06; A61P-009/12; C07D-233/00; C07D-233/16; C07D-223/00;
A61K-000/00; A61P-025/00; A61P-027/00; A61P-009/00; C07C-000/00;
C07D-000/00

Advanced IPC (V8) :

C07D-223/16 [2006-01 A F I R - -]; A61K-031/33 [2006-01 A - I R - -];
A61K-031/55 [2006-01 A L I R - -]; A61K-031/55 [2006-01 A - I R - -];
A61P-025/02 [2006-01 A L I R - -]; A61P-027/02 [2006-01 A L I R - -];
A61P-027/06 [2006-01 A L I R - -]; A61P-009/12 [2006-01 A L I R - -];
C07D-223/16 [2006-01 A - I R - -]; C07D-233/00 [2006-01 A - I R - -];
C07D-233/16 [2006-01 A - I R - -]

Core IPC (V8) :

C07D-223/00 [2006 C F I R - -]; A61K-000/00 [2006 S - I R - -];
A61K-031/33 [2006 C - I R - -]; A61K-031/55 [2006 C L I R - -];
A61K-031/55 [2006 C - I R - -]; A61P-025/00 [2006 C L I R - -];
A61P-027/00 [2006 C L I R - -]; A61P-009/00 [2006 C L I R - -];
C07C-000/00 [2006 S - I R - -]; C07D-000/00 [2006 S - I R - -];
C07D-223/00 [2006 C - I R - -]; C07D-233/00 [2006 C - I R - -]

US Patent Class :

514213000 540594000

Designated States :

EP--80779

Regional States: AT BE CH DE FR GB IT LI LU NL SE

EP--80779

Regional States: AT BE CH DE FR GB IT LI LU NL SE

Abstract :

EP--80779 A

An alpha-2 antagonist compsn. comprises a carrier and a 3-benzazepine cpd. of formula (I) or its pharmaceutically acceptable acid addn. salt. (R is 1-3C alkyl or allyl. X is halo). Most pref. (I) is 6-chloro-2,3,4,5-tetrahydro-3-methyl-1H-benzazepine (Ia) used as its hydrochloride salt. Esp. (I) are used to reduce intraocular pressure (treatment of glaucoma); as cardiovascular agents (treatment of congestive heart failure, angina pectoris and thrombosis) and as antihypertensives. They have no direct effect on pupil size and no effect on heart rate or blood pressure in normotensive subjects.

Manual Codes :

CPI: B06-D04 B12-E01 B12-F01 B12-F02 B12-F05 B12-H02 B12-L04

Update Basic :

1983-24

Update Equiv. :

1983-28; 1983-29; 1983-31; 1983-36; 1983-37; 1983-49; 1984-02; 1984-05;
1984-19; 1984-35; 1984-40; 1984-49; 1985-18; 1986-29; 1986-35; 1986-51;
1987-05; 1987-47